BridgeMD
TRANEX
EU CTIS ID: 2024-513573-49-00
What this study is testing
The objectives of this study are twofold, (1) to investigate whether tranexamic acid reduces the volume of blood loss and number of allogenic transfusion, and (2) to investigate the extend of fibrinolysis during burn excisional surgery.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Patients scheduled for burn excisional surgery 2. An expected blood loss of ≥250ml based on the estimation by the performing surgeon on the basis of: (1) 2 % body surface area excision planned (100-200 cc / %TBSA, based on retrospective data from Burn Centre Rotterdam), (2) operation technique used (some techniques show more blood loss than others), (3) time after burn trauma (i.e. expected healing). - ≥18 year
You likely can't join if
- Patients with a recorded coagulopathy in their history - Severe kidney failure (creatinine >500 umol/L) - Allergy for tranexamic acid - Acute venous-/arterial thrombosis (ongoing thrombosis). A history of thrombosis is NOT an exclusion criterion - Diffuse intravascular coagulation - Pregnancy - History of epilepsy
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.